Esophageal squamous cell carcinoma

This trial is testing whether giving a combination of two immunotherapies (ipilimumab and sintilimab) along with chemotherapy and radiation before surgery can completely eliminate cancer cells in people with locally advanced esophageal cancer. About 44 adults with resectable esop…

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find …

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study tests a drug called I-DXd in 60 people with advanced esophageal cancer that has worsened after prior treatments. I-DXd is designed to attach to cancer cells and deliver a toxic payload to destroy them. The main goal is to see how many patients' tumors shrink or disappe…

This study tests new drug combinations (including an antibody-drug conjugate) with the immunotherapy pembrolizumab, with or without chemotherapy, for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 participants will join to see if…

This clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…

Researchers test whether combining sacituzumab tirumotecan and tislelizumab can shrink advanced esophageal squamous cell carcinoma that has worsened after prior immunotherapy. The trial enrolls 28 adults whose cancer is not suitable for surgery or definitive chemoradiation. Parti…

Researchers are testing whether a short, focused course of radiotherapy combined with immunotherapy and chemotherapy can shrink locally advanced esophageal squamous cell carcinoma before surgery. Participants receive three cycles of camrelizumab plus nab-paclitaxel and carboplati…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This study tests several new drug combinations, with or without the immunotherapy pembrolizumab, in people with advanced esophageal cancer that has continued to grow after standard treatment. About 230 participants will receive different drug regimens to see which are safest and …

This trial tests whether giving a combination of adebrelimab, famitinib, and chemotherapy before surgery can eliminate cancer cells in people with esophageal squamous cell carcinoma. The study enrolls 24 adults with resectable, locally advanced tumors. Participants receive two cy…

This phase 2 trial is testing whether adding interferon gamma to the immunotherapy drug camrelizumab, along with chemotherapy, can help shrink tumors before surgery in people with locally advanced esophageal squamous cell carcinoma. The goal is to see if this combination increase…

This phase II trial tests a new drug called SKB500 in combination with standard chemotherapy and immunotherapy for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The study will evaluate how well the combination shrinks tumors and how sa…

This phase 3 trial is testing whether an experimental drug called lerotinib can help people with advanced esophageal cancer that has progressed after at least two prior treatments. Participants are randomly assigned to receive either lerotinib or a standard chemotherapy chosen by…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study is testing a drug called tislelizumab combined with chemotherapy as a first treatment for people with advanced stomach or esophageal cancer that cannot be removed by surgery or has spread. It focuses on racial and ethnic minority groups in the US, including Black, Hisp…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…

This trial is testing whether a special radiation technique, called lymphocyte-sparing radiotherapy, can reduce the drop in immune cells (lymphocytes) that often happens during standard chemoradiation for esophageal cancer. The study will compare this new approach to conventional…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced esophageal cancer that has worsened after standard treatments like platinum chemotherapy and immunotherapy. About 510 adults will be randomly assigned to receive either I-DXd or a standard ch…

This Phase 3 trial tests whether patients with esophageal cancer who respond well to initial drug therapy can safely avoid surgery and instead receive chemoradiotherapy to preserve their esophagus. Over 1,000 participants will be randomly assigned to either surgery or organ prese…

This trial is investigating the best time to give immunotherapy for people with advanced esophageal cancer that cannot be removed by surgery. Participants will receive either immunotherapy before chemoradiation or after, to see which sequence helps control the cancer longer. The …

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This trial investigates whether giving chemotherapy (docetaxel and nedaplatin) after surgery can prevent esophageal cancer from returning. Patients with a certain stage of thoracic esophageal squamous cell carcinoma who had their tumor fully removed are randomly assigned to recei…

This trial compares two liquids—hyaluronic acid and hydroxyethylamide—used to lift early-stage esophageal tumors before endoscopic removal. Doctors inject one of these solutions under the cancer to create a cushion, making it safer and easier to cut out. The study measures how mu…

This large Phase 3 trial tests a new drug called YL201 against standard chemotherapy in 440 people with advanced esophageal cancer that has worsened after initial treatment. YL201 is a targeted therapy designed to deliver chemo directly to cancer cells. The study aims to see if i…

This study tests a new combination of drugs (BL-B01D1 plus tislelizumab, with or without chemotherapy) as a first treatment for people with advanced esophageal cancer that cannot be removed by surgery. About 90 participants will be randomly assigned to receive either the new comb…

This early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…

This study investigates whether starting local treatments like radiation or surgery early or later alongside immunotherapy improves outcomes for people with esophageal cancer that has spread to a limited number of spots. Participants receive standard chemoimmunotherapy plus local…

This clinical trial compares two approaches for treating locally advanced esophageal squamous cell carcinoma before surgery. One group receives the immunotherapy drug cardonilizumab combined with chemotherapy, while the other receives standard chemoradiotherapy. The goal is to se…

This phase 2 trial tests a new drug called vebrekotuzumab, which delivers a powerful toxin directly to cancer cells that have a protein called EGFR. It is being tested alone or with an immunotherapy drug in 104 patients whose esophageal cancer has stopped responding to initial tr…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…

This study tests whether adding a single, low dose of radiation to the small intestine can make a standard immunotherapy-plus-chemotherapy regimen work better for people with esophageal cancer that cannot be easily removed by surgery. About 43 adults with borderline resectable or…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…

This phase II trial is testing whether combining the immunotherapy drug adebrelimab with two chemotherapy drugs (nab-paclitaxel and carboplatin) before surgery can help patients with borderline resectable esophageal cancer. The goal is to increase the chance of completely removin…

This phase 2 trial is testing a combination of three drugs—adebrelimab, apatinib, and tegafur—in 32 people with advanced esophageal cancer that has not responded to first-line immunotherapy. The goal is to see if this new mix can shrink tumors or slow the disease. Participants wi…

This study tests whether giving two drugs (anlotinib and bemocizumab) before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 25 adults with stage II-IIIB disease will receive the combination, then undergo surgery. The main goal is…

This study tests whether combining the immunotherapy drug camrelizumab with chemotherapy and radiation can shrink advanced esophageal cancer enough to avoid surgery. About 164 patients with stage II to IVa esophageal squamous cell carcinoma will receive one of two drug combinatio…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This study looks at two approaches for people with a type of esophageal cancer that shrank after initial chemo-immunotherapy. One group will have surgery to remove the tumor, while the other will get a combination of radiation and chemotherapy instead. Both groups will also recei…

This study looks at whether giving immunotherapy (adebrelimab) plus chemotherapy at different times of day changes how well it works for people with esophageal cancer. 90 participants will be split into three groups based on infusion timing before surgery. The main goal is to see…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. Ab…

This study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tum…

This study tests a drug called tislelizumab in people aged 70 and older with advanced esophageal cancer who are not healthy enough for standard chemotherapy. The drug is given through an IV and aims to help patients live longer and with better quality of life. Researchers will tr…

This study tests whether adding the immunotherapy drug iparomlimab after standard chemoradiation can help older adults (70+) with inoperable esophageal cancer live longer without the disease getting worse. About 52 participants will receive the drug for one year after chemoradiat…

This study tests whether adding adalimumab to standard chemotherapy and radiation before surgery can help eliminate esophageal cancer more effectively. About 37 adults with resectable esophageal squamous cell carcinoma will receive this combination. The main goal is to see how ma…

This phase 2 trial tests a drug called HLX43 in 102 people with advanced esophageal cancer that did not respond to or could not tolerate standard first-line therapy. HLX43 is an antibody-drug conjugate designed to deliver a chemotherapy agent directly to cancer cells. The study a…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy and immunotherapy for people with advanced solid tumors. About 110 adults with good overall health will receive the treatment to see if tumors shrink or stop growing. The goal is to find a sa…

This early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly t…

This early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…

This study tests whether giving immunotherapy and chemotherapy before radiation works better than the standard chemoradiation for people with advanced esophageal cancer that cannot be removed by surgery. About 92 adults with stage III-IVA esophageal squamous cell carcinoma will b…

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation before surgery helps people with a certain type of esophageal cancer live longer. About 422 adults with stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal cancer who…

This study tests a new drug called QLC5508 against standard chemotherapy in people with advanced esophageal cancer that has worsened after prior treatment. About 466 adults will be randomly assigned to receive either QLC5508 or a chemotherapy chosen by their doctor. The main goal…

This study tests a combination of three drugs (JS212, JS001, and 5-FU) in 280 people with advanced esophageal squamous cell carcinoma that cannot be cured by surgery. The goal is to see if the combo is safe and can shrink tumors or slow the disease. Participants must not have had…

This phase 3 trial tests whether adding two drugs—toripalimab and capecitabine—after standard chemoradiation can prevent esophageal cancer from coming back. About 242 adults with advanced esophageal cancer who finished chemoradiation without progression will be enrolled. The goal…

This study tests whether a combination of tislelizumab (an immunotherapy) and chemotherapy can shrink advanced esophageal tumors enough to allow surgery. Thirty patients with initially inoperable cancer will receive 2-4 cycles of the drug combo, then be reassessed for surgery. Th…

This study tests whether adding immunotherapy (a drug that helps the immune system fight cancer) after standard chemotherapy and radiation can help people with advanced esophageal cancer live longer without the disease getting worse. About 452 adults with a specific type of esoph…

This study looks at whether intensive nutritional support can help patients with advanced esophageal cancer who are receiving chemotherapy and immunotherapy before surgery. About 118 participants will be randomly assigned to either standard care or extra oral nutrition supplement…

This study tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for people with advanced or returning esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can shrink or control the cancer better. Thirty adults age…

This study tests whether adding the immunotherapy drug camrelizumab to a short course of chemotherapy and radiation can better control advanced esophageal cancer that cannot be removed by surgery. About 98 participants will receive one of two treatment schedules. The goal is to s…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This study explores whether monitoring tumor DNA in the blood (ctDNA) can help guide treatment for esophageal cancer. Researchers will give patients immunotherapy and chemotherapy, followed by chemoradiotherapy, and track ctDNA levels to see if they predict outcomes. The goal is …

This study tests a new oral drug called KC1036 combined with standard immunotherapy (toripalimab) and chemotherapy (paclitaxel and cisplatin) as a first treatment for advanced esophageal cancer that has spread or come back. The trial will enroll 60 adults aged 18-75 who have not …

This phase 2 trial tests whether adding two newer drugs—serplulimab (an immunotherapy) and nimotuzumab (a targeted therapy)—to standard chemoradiation before surgery can improve outcomes for people with resectable esophageal cancer. About 46 participants will receive the combinat…

This phase 2 trial is testing whether a combination of the immunotherapy drug bemosubaiabimab, the targeted pill anlotinib, plus radiation and chemotherapy can help people with oligometastatic esophageal cancer—cancer that has spread to a few spots. About 28 participants will rec…

This Phase 2 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy can shrink advanced esophageal tumors enough to allow surgery. About 45 people with unresectable esophageal squamous cell carcinoma will receive the combination, followe…

This study is testing whether giving the immunotherapy drug adebrelimab along with standard chemotherapy before surgery can help people with locally advanced esophageal cancer. About 42 participants will receive the treatment every 3 weeks, then have surgery. The main goal is to …

This study tests a two-step approach for people with advanced esophageal cancer that cannot be removed by surgery. First, patients receive a combination of immunotherapy and chemotherapy. Then, based on how well the tumor responds, they get either the same drugs plus radiation or…

This study is testing whether a chemotherapy pill (oral paclitaxel) combined with radiation can safely treat advanced esophageal cancer that cannot be removed by surgery. It is for people aged 70 or older, or those who cannot tolerate standard IV chemo. The goal is to control the…

This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help eliminate or shrink esophageal cancer more effectively. About 25 people with stage II/III esophageal squamous cell carcinoma will receive the combination, then have surgery. Rese…

This early-phase study tests a new cell therapy called GK01 in 10 people with advanced lung or esophageal cancer that no longer responds to standard treatments. The main goal is to check safety and how the body handles the therapy. Researchers will also look for early signs of tu…

This study tests a combination of an immunotherapy drug (ivonescimab) with two chemotherapy drugs before surgery for people with a certain type of advanced esophageal cancer. The goal is to see if this approach can shrink tumors enough to improve long-term outcomes. About 45 adul…

This study tests a new approach for people with locally advanced esophageal cancer. Participants first receive a combination of immunotherapy and chemotherapy, then chemoradiation, followed by surgery. The goal is to see if this sequence can shrink tumors more effectively and imp…

This early-phase trial is testing a new drug, BC2027, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors or slow their growth. Participants re…

This early-phase trial tests whether giving an extra, higher dose of radiation guided by MRI can improve outcomes for people with a type of esophageal cancer. About 30 participants will receive standard chemoradiotherapy plus two extra radiation boosts. The main goal is to find t…

This study tests whether adding low-dose or standard radiotherapy to the usual combination of immunotherapy (anti-PD-1) and chemotherapy can help people with metastatic esophageal squamous cell carcinoma. About 100 adults who have not had prior treatment will participate. The goa…

This Phase 1 trial tests TQB6411, an antibody-drug conjugate designed to bind to EGFR and c-Met proteins on tumor cells, blocking their growth signals and releasing a toxin to kill the cells. The study will enroll 216 adults with advanced malignant tumors to find the safest dose …

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This study tests whether giving chemotherapy plus immunotherapy before treatment can shrink esophageal tumors enough to remove them with an endoscope (a thin tube down the throat) instead of major surgery. About 60 adults with early-stage esophageal cancer will receive two or mor…

This study tests whether adding immunotherapy to a precise type of radiotherapy (sparing tumor-draining lymph nodes) and chemotherapy can help adults with advanced esophageal cancer live longer without the disease getting worse. About 432 participants will receive either the comb…

This study tests whether adding the drug cadonilimab to standard chemotherapy before and after surgery helps people with a certain type of esophageal cancer. About 90 adults with resectable, locally advanced cancer will take part. The goal is to see if the combination leads to mo…

This study tests whether two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy can help people with advanced esophageal cancer that has come back or spread. About 25 adults will receive the treatment for up to 24 months. The goal is to see if the combination sh…

This study tests whether injecting a cancer-killing virus directly into tumors, combined with standard chemotherapy and an immunotherapy drug, can shrink advanced esophageal cancer enough to allow surgery. About 40 adults with unresectable locally advanced esophageal squamous cel…

This study tests whether the drug adebrelizumab can help prevent esophageal cancer from returning after surgery. About 142 adults who had their cancer completely removed will receive either adebrelizumab or a placebo. The main goal is to see how long patients stay cancer-free, an…

This study tests a new drug called envafolimab combined with standard chemotherapy given before surgery for people with a type of esophageal cancer that can be removed. The goal is to see if this combination can shrink the tumor more effectively, potentially leading to better lon…

This study tests a combination of two drugs, afatinib and palbociclib, in people with advanced esophageal cancer that has come back or spread after prior treatment. The goal is to find a safe dose and see if the combo can shrink tumors. About 45 adults aged 18 to 75 with a specif…

This study tests whether combining the immunotherapy adbelimumab with chemotherapy and the targeted drug apatinib can help shrink esophageal tumors before surgery. About 35 adults with resectable esophageal squamous cell carcinoma will receive four cycles of the drug combo, then …

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This phase II trial tests whether adding the drug surufatinib to standard chemo-immunotherapy and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. The study will enroll 69 participants in China and track how long they live without the c…

This phase 2 trial is testing whether a shorter, more intense course of radiation (hypofractionated) is safer and more effective than the standard longer course for people with advanced esophageal cancer that cannot be surgically removed. All participants first receive two cycles…

This phase II trial tests whether adding itraconazole, a common antifungal medication, to standard chemoradiation can improve outcomes for people with resectable esophageal cancer. About 78 participants will receive itraconazole before and after standard treatment, then undergo s…

This study is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy before and after surgery can help patients with locally advanced esophageal cancer. About 30 participants will receive three cycles of the combination before surgery, then continue ad…

This study tests whether combining the drug camrelizumab with chemotherapy before surgery can help people with esophageal cancer keep their esophagus instead of having it removed. About 283 adults with early-stage esophageal cancer will receive the treatment and be monitored for …

This phase 2 trial is testing whether a drug called ivonescimab, given together with a short course of targeted radiation, can help people with advanced esophageal cancer that has worsened after first treatment. The study will enroll 37 adults and track how long they live without…

This pilot study tests a two-step treatment for T4 esophageal cancer, where the tumor has spread to nearby organs. First, patients receive up to 8 cycles of chemotherapy with docetaxel, cisplatin, and fluorouracil. If the tumor shrinks enough, they then get a lower dose of radiat…

This phase 2 trial is testing whether a personalized treatment plan based on a biomarker (CPS score) can improve outcomes for people with a certain type of esophageal cancer. Participants will receive a combination of the immunotherapy drug serplulimab, chemotherapy, and possibly…

This phase 2 trial tests whether adding high-dose-rate brachytherapy (internal radiation) to the immune therapy drug nivolumab can improve outcomes for people with advanced esophageal cancer that has not been fully controlled by standard chemoradiation. About 60 participants will…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This trial tests a new way to spot esophageal cancer early using a swallowable sponge called EsophaCap, which collects cells from the esophagus. A lab test then looks for DNA changes linked to cancer. The study enrolls adults with or suspected of having esophageal cancer, as well…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

The SYNERGY study is developing a blood test that looks for tiny genetic molecules called microRNAs to detect esophageal squamous cell carcinoma (ESCC) at an early, more treatable stage. Researchers will collect blood samples from 600 adults with and without ESCC to build and val…

This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. Th…

This study tests a portable microscope with artificial intelligence to help doctors spot early signs of esophageal cancer during a routine scope exam. Researchers will enroll 200 adults in Brazil and the United States who are already scheduled for screening. The goal is to see if…

This study tests an artificial intelligence system that assists doctors in determining how deep early esophageal cancer has spread, using endoscopic ultrasound images. The goal is to improve the accuracy of preoperative staging, which helps guide treatment decisions. Researchers …

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study reviews the medical records of about 4000 people who had surgery for esophageal cancer. The goal is to see how the amount of cancer left at the edges of the removed tissue affects how long people live. No new treatments are given; the study only looks at past informati…

This study looks at whether changes in DNA methylation—a type of epigenetic marker—can help predict if esophageal cancer will come back soon after surgery. Researchers will analyze tumor tissue from 150 patients who had their cancer removed and track who experiences a recurrence …

This study investigates whether DNA methylation patterns in tumor biopsy samples can predict how well esophageal cancer patients will respond to chemotherapy. Researchers aim to develop a model that identifies patients unlikely to benefit from standard chemo drugs like Fluorourac…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study is looking at whether a blood test (liquid biopsy) can find tiny bits of cancer DNA left behind after treatment for esophageal cancer. Researchers will collect blood samples from 248 patients before, during, and after standard treatment. The goal is to see if this test…

This study is a large registry that will collect information from about 1,900 people with advanced cancer of the esophagus or stomach who are receiving palliative treatment in Germany. The goal is to understand what treatments are actually used in everyday practice and how patien…

This study follows 1,100 people with esophageal cancer to see how often the cancer spreads to a specific lymph node near the windpipe (subcarinal node). Researchers will also look for factors that make spread more likely. The goal is to help doctors decide whether to remove these…

This study observes 1,852 people with esophageal cancer to see how often the cancer spreads to a specific lymph node in the chest (left tracheobronchial lymph node). Researchers will track who develops this spread and look for risk factors. The goal is to better understand the di…